Guí a OncoSur de me l anoma 116 > LECTURAS RECOMENDADAS Chattopadhyay C, Kim DW, Gombos DS, et al. Uveal melanoma: from diagnosis to treatment and the science in between. Cancer 2016;122(15):2299-312. Glitza Oliva I, Tawbi H, Davies MA. Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer J 2017;23(1):68-74. Harbour JW, Shih HA. Initial management of uveal and conjunctival melanomas. In: Atkins MB, editor. 2018. UpToDate. Available from: www-uptodate-com/contents/initial-management-of-uveal-and-conjunctivalmelanomas?search=melanoma%20uveal&source=search_result&selectedTitle=1~24&usage_type=default&display_rank=1 Shoushtari AN, Munhoz RR, Kuk D, et al. The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 2016;15;122(21):3354-62. Tyrrell H, Payne M. Combating mucosal melanomas: recent advances and future perspectives. Melanoma Manag 2018;5(3):MMT11. Available from: futuremedicine.com/doi/pdf/10.2217/mmt-2018-0003 BIBLIOGRAFÍA 1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664. 2. Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 2013;19:4488. 3. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734. 4. Kim HK, Lee S, Kim K, et al. Efficacy of BRAF inhibitors in Asian metastatic melanoma patients: potential implications of genomic sequencing in BRAF mutated melanoma. Trasl Oncol 2016;9:557-64. 5. Postow MA, Luke JJ, Bluth MJ, et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013;18:726. 6. Schaeffer T, Satzger I, Gutzmar R, et al. Clinics, prognosis and new therapeutic options in patients with mucosal melanoma: a retrospective analysis in 75 patients. Medicina 2017;96:e5753. 7. D’Angelo SP, Larkin J, Sosman JA, et al. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. J Clin Oncol 2017;35:226. 8. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191. 9. Schmittel A, Bechrakis NE, Scheilbenbogen C, et al. Prognostic factors for development of metastatic disease in ocular melanoma: 5 years follow-up of 271 patients (abstract). Proc Am Soc Clin Oncol 2003;22:711a. 10. Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol 2018;36:1232-9. 11. Carvajal RD, Sosman JA, Quevedo JF, et al. Effect of selumetinib versus chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA 2014;311:2397-405. 12. Piulats Rodríguez J, Ochoa de Olza M, Codes M, et al. Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial [abstract]. J Clin Oncol 2014;32:9033. 13. Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer 2016;122:3344. 14. Heppt HV, Amaral T, Käler K C et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retroscpective, multi-center study. J Immunother Cancer 2019;7:299.
RkJQdWJsaXNoZXIy OTI4NTYw